STAT

Opinion: Innovation in biotech R&D: New resources offer new hope

Refining and replicating new R&D models created by several foundations, ambitious venture firms, and some universities will take the life sciences sector to new heights.
Erricka Hager (right) is a participant in the NIH's All of Us Research Program, an example of several innovative research and R&D programs underway in the U.S.

Public optimism about American health care seems in short supply if you read the news, which is dominated by coverage of partisan fights over the Affordable Care Act and the continuing crisis of opioid addiction. But innovation in the life sciences sector offers reason to cheer. We’re seeing vital new approaches to research and development driven by the private and philanthropic sectors, focused both on how we finance research and development and how we conduct it.

I’ll start with the finance side of the equation. The that the National Institutes of Health risked losing its edge in biomedical innovation. Since then, the landscape has shifted: We are now seeing significant increases in funding for NIH, which is great news.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks